Evaxion Completes Phase 2 Trial Extension for Personalized Cancer Vaccine EVX-01

summarizeSummary

Evaxion A announced the successful completion of the one-year extension of its Phase 2 trial for personalized cancer vaccine EVX-01, with three-year efficacy data expected in the second half of 2026.

check_boxKey Events

• Phase 2 Trial Extension Completed

  Evaxion announced the successful completion of the one-year extension of its Phase 2 trial for the personalized cancer vaccine EVX-01, with the last patient visit now concluded.

• Three-Year Data Expected H2 2026

  Patients will continue to be monitored, and three-year clinical efficacy data from the trial is anticipated to be presented in the second half of 2026.

• Strong Prior Efficacy Data Reiterated

  The company reiterated encouraging one- and two-year data, including a 75% Objective Response Rate and 92% durable clinical benefit at two years, with no relapses observed.

• AI-Immunology™ Platform Validation

  The trial demonstrated EVX-01 induced an immune response in all patients, with 81% of targeted neoantigens generating potent specific T-cell responses, validating the AI-Immunology™ platform.

auto_awesomeAnalysis

Evaxion A has successfully completed the one-year extension of its Phase 2 trial for the personalized cancer vaccine EVX-01, marking a significant operational milestone. While no new clinical data was released in this filing, the completion of this phase de-risks the trial timeline and sets the stage for the highly anticipated three-year efficacy data, expected in the second half of 2026. The reiteration of strong prior data, including a 75% Objective Response Rate and 92% durable clinical benefit at two years, provides a positive backdrop and validates the company's AI-Immunology™ platform. Investors should monitor for the upcoming data release as the next major catalyst.